CNTB — Connect Biopharma Holdings Limited - Ordinary Shares
Session close: $1.10. Regular-session share volume: 67,682,239. Change from previous close: +10.89%.
News sources
Company news Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy · Company news BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5 · Company news Connect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart Significantly Reduced The Rate Of Treatment Failure Compared To Placebo Through One Month By 81%; Rademikibart Significantly Reduced The Rate Of New Moderate To Severe COPD Exacerbations Through One Month By 85%